Long non‑coding RNA LINC00460 predicts poor survival and promotes cell viability in pancreatic cancer

Abstract

Emerging evidence has demonstrated that long non-coding RNAs (lncRNAs) possess great potential as vital biomarkers and powerful therapeutic targets in various diseases. In the present study, differentially expressed transcripts in pancreatic cancer (PC) were identified, and a competing endogenous RNA (ceRNA) network was constructed using The Cancer Genome Atlas database. An independent cohort consisting of 59 patients with PC was used to validate the clinical value of the identified lncRNA. Cell viability and colony formation assays were used to evaluate the biological functions of the lncRNA in PC cells. The present bioinformatic analysis revealed that LINC00460 was upregulated in PC samples with a prognostic significance. In the ceRNA network, it potentially targeted the microRNA-503/cyclin D1 axis. The results of real-time quantitative PCR confirmed that LINC00460 was significantly upregulated in cancer tissues and was associated with poor survival of patients with PC. The expression levels of LINC00460 were significantly associated with tumor size, but not with age, sex, differentiation, lymph node metastasis, vascular invasion and tumor stage. Through univariate and multivariate analysis, LINC00460 was characterized as an independent prognostic biomarker for PC. Further in vitro experiments demonstrated that suppressing LINC00460 using small interfering RNA inhibited viability and colony formation of PC cells. In summary, LINC00460 may be an independent prognostic biomarker for PC and may serve as an oncogenic lncRNA that promotes PC cell growth. Further in-depth exploration is required to reveal the specific biological mechanism of LINC00460 in PC cells.

LINC00460 Is a Dual Biomarker That Acts as a Predictor for Increased Prognosis in Basal-Like Breast Cancer and Potentially Regulates Immunogenic and Differentiation-Related Genes

“…Several reports show that LINC00460 is a marker for poor OS prognosis across different tumors, such as CESC ( 48 ), HNSC ( 80 ), KIRC ( 81 ), LUAD ( 49 ) and PAAD ( 82 ). In addition, we describe here that LINC00460 high expression is significantly associated with poor survival in three different tumors (GBM, LGG and SARC) but related with a favorable survival rate in BRCA, i.e.…”

LINC00460 promotes pancreatic cancer progression by sponging miR‐491‐5p

“…In accordance with this finding, a recent study based on database and clinical sample analysis identified LINC00460 as a key lncRNA with prognostic value in pancreatic cancer. 36 These results suggest that LINC00460 might be regarded as a candidate for detection and therapy of PDAC. However, there is no research fully investigating the biological roles or mechanism of LINC00460 in PDAC.…”

Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis

“…Previous study suggested that LINC00460 level exhibits high expression in human prostate cancer tissues and cell lines, and downregulation of LINC00460 suppresses cell proliferation and promotes cell apoptosis in prostate cancer, which is consistent with our study [ 12 ]. Moreover, the LINC00460 level is positively related to tumor size, and predicts poor survival of PC patients [ 13 ]. Interestingly, our findings indicated that LINC00460 level was increased in pancreatic cancer cell lines (SW1990, HPAC, PaCa-2, CFPAC-1, CAPAN-1) compared to normal human pancreatic duct cells.…”

“…Interestingly, LINC00460 downregulation could depress PC cell proliferation and promote cell apoptosis, mediated by PI3K/AKT pathway [ 12 ]. Moreover, LINC00460 may be a promising biomarker for diagnosis and prognosis of PC, and predicts poor survival of PC patients [ 13 ]. However, the underlying mechanism involved in LINC00460 playing its role in the proliferation, migration and invasion of pancreatic cancer cells has been uninvestigated.…”